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Background: clinical applications of microarrays
While  microarrays  were  rapidly  accepted  in  research 
applications, incorporating them in clinical settings has 
required over a decade of benchmarking, standardization 
and  the  development  of  appropriate  analysis  methods. 
Extensive  cross-platform  and  cross-laboratory  analyses 
demonstrated  the  importance  of  low-level  processing 
choices  [1-3],  including  data  summarization,  normali-
zation, and adjustment for laboratory or ‘batch’ effects 
[4], on outcome accuracy. Some of this work was done 
under the auspices of the Food and Drug Administration 
(FDA),  most  notably  the  Microarray  Quality  Control 
(MAQC)  studies,  which  were  developed  specifically  in 
order to determine the utility of microarray technologies 
in  a  clinical  setting  [5,6].  Microarray-measured  gene 
expression  signatures  now  form  the  basis  of  several 
FDA-approved  clinical  diagnostic  tests,  including 
MammaPrint, and Pathwork’s Tissue of Origin test [7,8].
With  high-throughput  sequencing  still  in  its  infancy, 
many questions remain to be addressed before any hope 
of  achieving  approval  for  clinical  applications  is 
warranted. Although a study on the scale of the MAQC 
analyses  for  microarrays  has  yet  to  be  carried  out  for 
sequencing  (although  one  is  in  the  works),  there  is 
already evidence that similar technical biases are present 
in sequencing data, and these will need to be understood 
and adjusted for to enable use of these new technologies 
in a clinical setting. In this commentary, we present some 
of these known biases and discuss the current state of 
solutions  aimed  at  addressing  them.  Looking  ahead  to 
the  application  of  this  new  technology  in  the  clinical 
setting, we see both hurdles and promise.
Bias and batch effects in high-throughput assays
Biases  arise  when  an  observed  measurement  does  not 
reflect the quantity to be measured due to a systematic 
distorting  effect.  For  a  concrete  example  from  micro-
arrays, non-specific hybridization at microarray probes 
produces an observed intensity that is not an unbiased 
measure of the presence of the target sequence in the 
population  being  studied.  Thorough  investigation  has 
revealed  that  the  chemical  composition  of  microarray 
probes influences this effect, and analysis methods have 
been developed to alleviate it [9].
Similarly,  batch  effects,  whereby  external  factors,  for 
example, time or technician, have a systematic influence 
on experimental outcomes across a condition, have been 
seen  in  many  high-throughput  technologies,  and  can 
cause  confounding  without  proper  study  design  and 
analysis techniques [4,10].
So far, there is evidence that these issues are present in 
experiments  employing  high-throughput  sequencing 
data, indicating that similar precautions and methodo-
logical developments will be necessary before sequencing 
data can be used with confidence in the clinic.
Bias in base-call error rates
High-throughput  sequencing  involves  the  parallel 
sequen  cing of millions of DNA fragments simultaneously. 
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time,  and,  at  each  step  or  cycle,  the  current  base  is 
determined through fluorescent detection. For a review, 
see Holt and Jones [11]. Although sequencing platform 
chemistries differ, in all cases care must be taken to avoid 
introducing bias at this early stage.
Focusing on the Illumina Genome Analyzer platform, 
base-call errors are not randomly distributed across the 
cycle positions in sequenced reads [12]. Although not as 
extensively  studied,  similar  biases  have  been  observed 
and  low-level  signal  correction  methods  have  been 
developed for other sequencing platforms [13].
Incorrect  base  calls  can  have  a  deleterious  impact 
downstream in aligning reads to the reference genome 
(resulting in fewer or incorrect alignments) and in variant 
detection (contributing to false-positive variant calls). In 
experiments  aimed  at  detecting  variants  in  genomic 
DNA, concern about false positives may lead researchers 
to employ stringent filtering criteria. Many researchers 
are hypothesizing that the discovery of rare variants will 
be a crucial next step in understanding the genetic causes 
of complex diseases [14], and overly strict filtering criteria 
may  eliminate  exactly  the  variants  of  most  interest  and 
impact. By improving the quality of nucleotide calls, either 
Figure 1. Effect of base-calling improvements on error bias. This 
figure is based on figures from Bravo and Irizarry [15]. Choosing a 
site that was a false-positive variant as determined by MAQ [28], the 
authors examined the pattern of nucleotide calls according to the 
read cycle the different calls occurred at. (a) Results with the default 
base-calling software; (b) results after application of the base-calling 
method of Bravo and Irizarry. The x-axis shows read cycle and the 
colored points indicate the percentage of calls at each cycle that 
were made for a particular nucleotide. In (a), the letter T becomes 
much more frequent in reads that align to the SNP site only at later 
sequencing cycles, indicating a technical bias in base calls at this 
position, while the plot in (b) shows a strong reduction in this bias. In 
addition, the location is no longer determined as a variant by MAQ 
after the improved base calling.
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Figure 2. Effect of mappability and GC content on coverage. 
(a) Mean tag counts in 50-bp bins, with error bars, from a naked DNA 
sample from a ChIP-Seq experiment, showing that they depend on 
mappability and GC content. (b) 97.4% of bins have GC percentages 
between 0.2% and 0.56%, as marked by the vertical dashed lines. This 
figure is reproduced with permission from Kuan et al. [21].
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Page 2 of 5through  better  base  calling  or  error  correction,  more 
accurate variant calls will be possible.
Alternative base-calling methods that reduce the cycle-
related bias in error rates have been developed (Figure 1) 
[15,16].  Numerous  error  correction  methods  have  also 
been developed to remove errors from reads after base 
calls have been made [17-20]. Since base calling requires 
the  raw  intensity  files,  which  many  laboratories  never 
receive  from  sequencing  centers,  re-calling  bases  is 
logistically burdensome, and error correction provides a 
potential alternative.
Coverage biases
Another long-observed phenomenon of high-throughput 
sequencing data is the strong, reproducible effect of local 
sequence content on the coverage of a genomic region by 
sequencing reads [12]. This phenomenon is analogous to 
probe effects for microarray platforms. For sequencing 
projects  where  coverage  levels  are  compared  across 
regions, such as RNA-Seq, chromosome immunoprecipi-
tation-sequencing (ChIP-Seq) or copy number detection, 
this phenomenon can be particularly problematic.
Researchers  carrying  out  ChIP-Seq  experiments  have 
observed a systematic relationship between coverage and 
GC content (Figure 2) [21]. Researchers using sequencing 
to measure copy number have also found adjusting for GC 
content improves precision [22]. Adjusting signal for GC 
content leads to improved results in both ChIP-Seq and 
copy number estimation with sequencing data [21,22].
Genomic regions that are identical or highly similar to 
one  another  create  ambiguity  in  alignment  to  the 
genome,  and  ambiguous  reads  are  generally  discarded. 
The  low  coverage  in  these  regions  can  produce  biased 
measurements or remove the regions from consideration 
in  downstream  analysis,  potentially  eliminating  impor-
tant signals from the data. Methods have been developed 
for  taking  this  mappability  property  into  account  to 
adjust the observed signal in these regions [21].
Figure 3. Batch effect for second-generation sequencing data from the 1000 Genomes Project. This figure is similar to one from Leek et al. 
[10]. Each row in the heat-map is data from a different HapMap sample processed in the same facility with the same platform (see Leek et al. [10] for 
a description of the data), shown for a 3-Mb region on chromosome 16, with data summarized in 10-kb bins. Data from each bin were standardized 
across samples, with blue representing 3 standard deviations below average, and orange representing 3 standard deviations above average. The 
rows are ordered by date, with black lines separating different processing days. The largest batch effect can be seen on the alternating pattern of 
blue and orange on days 223 to 241 and days 244 to 251.
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Page 3 of 5Some spatial biases seem to be unique to the sample 
preparation protocol being used. Hansen et al. [23] have 
shown  that  random  hexamer  priming  can  lead  to 
coverage  bias  in  RNA-Seq  analyses,  and  Li  et  al.  [24] 
present a model for the non-uniformity of RNA-Seq read 
coverage.  Both  papers  provide  solutions  to  adjust  for 
these biases and achieve more uniform coverage.
Batch effects
Batch effects arise when variability in the data correlates 
with  a  technical  variable,  such  as  processing  date, 
location or technician. Such effects have been observed 
in many different high-throughput experiments. Leek et 
al.  [10]  investigated  batch  effects  in  genomic  DNA 
sequencing  carried  out  as  part  of  the  1000  Genomes 
Project [25]. To investigate whether batch effects were 
present in a subset of this sequencing data, Leek et al. 
compiled a set of aligned sequencing data sets that were 
produced in the same location at different dates. After 
summarization  and  normalization  of  the  data,  clear 
spatial patterns can be seen in several of the samples, and 
the patterns are correlated with the technical variable of 
processing date (Figure 3). Patterns like these could lead 
to false conclusions in experiments where the sequencing 
coverage is related to the condition of interest, such as 
copy-number or peak height.
The primary way of avoiding batch effects is through 
careful  experimental  design.  Randomization  of  all 
experimental  variables  across  treatment  conditions 
should be employed to avoid systematic effects within a 
condition. In order to correct for these batch effects after 
the fact, they need to first be detected, and then adjusted 
for, be it through the use of covariates in linear models, 
or more involved procedures such as surrogate variable 
analysis  [26].  These  methods  will  work  best  when 
confounding  between  the  technical  variable  and  the 
outcome  of  interest  are  avoided;  thus,  careful  experi-
mental design is essential.
One  challenge  of  using  sequencing  technologies  in 
clinical applications is that conclusions are likely to be 
drawn by comparing newly acquired data with genome 
profiles  derived  from  previously  collected  data.  Inter-
preting findings derived from this type of comparison is 
made difficult by the batch effect. Better understanding 
of batch-to-batch variation and development of single-
sample  methods  such  as  fRMA  [27]  will  be  important 
steps forward in addressing this challenge.
Conclusion
Just as is the case for other high-throughput biological 
assays,  high-throughput  sequencing  presents  many 
challenges  when  it  comes  to  avoiding  bias  and  batch 
effects. Promising solutions to these problems are already 
in  development,  including:  low-level  improvements  in 
base calling and error correction, improved per-position 
data quality metrics, adjustments to coverage estimates 
to alleviate context-specific or protocol-specific effects, 
and  experimental  designs  that  minimize  potential 
confounding effects of batch. The lessons learned through 
the development of clinical applications of microarrays, 
such as the need for benchmark studies such as those 
conducted by the MAQC project, should help accelerate 
the process of incorporating high-throughput sequencing 
into the clinic.
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